$ARIA Recent Headlines Six stocks to watch 4:27 p.m.

New Post Public Reply Private Reply Replies (0) Message Board

Apr 12, 2014 at 10:00 AM

$ARIA Recent Headlines

Six stocks to watch 4:27 p.m. Feb. 26, 2014 - The Trading Deck
6 stocks to watch 4:34 p.m. Feb. 12, 2014 - The Trading Deck
Ariad falls after wild ride upward, while Care.com holds on to its gains 10:02 p.m. Jan. 27, 2014 - Russ Britt
Apple green ahead of earnings; Caterpillar tops gainers 4:42 p.m. Jan. 27, 2014 - Sue Chang
Ariad shares jump nearly 30% on rumors of Big Pharma takeover 2:43 p.m. Jan. 24, 2014 - Russ Britt
5 charts to watch 4:52 p.m. Jan. 15, 2014 - The Trading Deck
Apple closes lower; B. of A. rises on analyst call 5:15 p.m. Jan. 2, 2014 - Wallace Witkowski
Apple gains on China Mobile deal; homebuilders rally 4:33 p.m. Dec. 23, 2013 - Wallace Witkowski
Suspension is lifted for Ariad's leukemia drug 7:33 a.m. Dec. 23, 2013 - MarketWatch.com
J.C. Penney and more of the year's most profitable shorts 4:23 p.m. Dec. 9, 2013 - blogs.marketwatch.com
Hewlett-Packard, a cyclical green light and why silver is in trouble 9:50 a.m. Nov. 26, 2013 - Shawn Langlois
Ariad takes another pounding after leukemia treatment is pulled 1:14 p.m. Oct. 31, 2013 - Russ Britt
H-P has best day in four months on upbeat outlook 4:34 p.m. Oct. 9, 2013 - Sue Chang
Ariad plummets 70% after drug test patients have serious clotting issues 11:38 a.m. Oct. 9, 2013 - Russ Britt
FDA places partial hold on Ariad's Iclusig trials 8:16 a.m. Oct. 9, 2013 - MarketWatch.com
Dan Loeb makes bet on Disney 8:06 p.m. Aug. 14, 2013 - David Benoit
Onyx share surge lifts several boats in biotech harbor, including ETFs 11:33 a.m. July 1, 2013 - Russ Britt
SAC Capital Advisors likes this pharma stock 4:24 p.m. April 18, 2013 - Insider Monkey
Ariad Pharma up 6% to $20.09 11:35 a.m. Dec. 17, 2012 - Steve Gelsi
FDA OKs Iclusig to treat rare types of leukemia 2:06 p.m. Dec. 14, 2012 - MarketWatch.com

FDA Approves Novartis' ALK Inhibitor! Maybe...Really Soon? 3:07 p.m. April 11, 2014 - TheStreet.com
Causeway Capital's Sarah Ketterer Responds to GuruFocus Reader Questions 4:33 p.m. April 4, 2014 - GuruFocus.com
Mid-Day Market Update: Restoration Hardware Surges On Earnings; Endocyte Shares Drop 11:23 a.m. March 28, 2014 - benzinga.com
Mid-Day Market Update: Restoration Hardware Surges On Earnings; Endocyte Shares Drop 11:23 a.m. March 28, 2014 - benzinga.com
Mid-Morning Market Update: Markets Open Higher; BlackBerry Reports Smaller-Than-Expected Loss 9:22 a.m. March 28, 2014 - benzinga.com
Biggest Movers in Healthcare Stocks Now – MNKD ARIA CYH HALO 9:00 a.m. March 28, 2014 - InvestorPlace.com
Aria up premarket on buyout rumors 7:35 a.m. March 28, 2014 - Seeking Alpha
ARIA Stock Gets Big Boost From JAZZ Buyout Rumors 7:20 a.m. March 28, 2014 - InvestorPlace.com
Benzinga's Top #PreMarket Gainers 7:08 a.m. March 28, 2014 - benzinga.com
Novartis lung-cancer drug produces response in over half of patients 4:26 a.m. March 27, 2014 - Seeking Alpha
ARIAD Candidate in Phase II Study - Analyst Blog 6:10 p.m. March 26, 2014 - Zacks.com
Novartis Drug Shows Promise in Rare Lung Cancer 5:20 p.m. March 26, 2014 - The Wall Street Journal Interactive Edition
Novartis Targeted Lung Cancer Drug Highlighted in This Week's NEJM 5:14 p.m. March 26, 2014 - TheStreet.com
Large Cap Biopharmaceuticals Are Core Holdings After Sell-Off: AbbVie, Amgen, Gilead 8:12 a.m. March 26, 2014 - Seeking Alpha
Cramer's Mad Money - The 'What, Me Worry?' HMOs (3/25/14) 6:22 a.m. March 26, 2014 - Seeking Alpha
Morning Market Movers 8:39 a.m. March 25, 2014 - benzinga.com
Why Now Is The Time To Buy Ariad Pharmaceuticals 3:20 p.m. March 24, 2014 - Seeking Alpha
Looking For Value Among Biotechs After Precipitous Declines In Stock Price 12:26 p.m. March 24, 2014 - Seeking Alpha
Cramer's Mad Money - Which IPOs To Watch, Which IPOs To Ignore (3/17/14) 6:15 a.m. March 18, 2014 - Seeking Alpha
Perilous Reversal Watch: Ariad Pharmaceuticals (ARIA) 3:03 p.m. March 17, 2014 - TheStreet.com

Clinical Trial Results and Initiation, Endowment, Product Launches, and Appointments - Analyst Notes on Regeneron, Questcor, Jazz, Ariad, and BioMarin 8:00 a.m. April 11, 2014 - PR Newswire - PRF
Mallinckrodt to Buy Drugmaker Questcor Pharmaceuticals for about $5.6B; Tesla Rated "Outperform" by RW Baird 1:00 a.m. April 8, 2014 - ACCESSWIRE
Apollo Education Sinks on Disappointing Earnings; Rubicon Project Makes Grand Debut on NYSE 12:12 a.m. April 3, 2014 - ACCESSWIRE
Clinical Study Initiations, Stock Price Updates, and Strategic Agreements - Analyst Notes on Ariad, Jazz, Intercept, Community Health, and United Technologies 8:00 a.m. April 2, 2014 - PR Newswire - PRF
ARIAD Announces Appointment of Hugh Cole, Senior Pharmaceutical-Industry Executive, as Chief Business Officer 7:35 a.m. April 2, 2014 - BusinessWire - BZX
Technical Pointers on Top Gainers -- Research on ARIAD Pharma, Arotech, Restoration Hardware Holdings, and Sprouts Farmers Market 12:52 p.m. March 31, 2014 - PR Newswire - PRF
Newmont Mining Corp Denies Cutting Output; Indonesian Copper and Gold Mine and Ford Raised CEO Alan Mulally's Compensation by 11% 12:16 a.m. March 31, 2014 - ACCESSWIRE
Insider Trading Research -- Alerts for Ariad Pharmaceuticals, Cell Therapeutics, Staples, Sirius XM, Facebook, and Bank of America 8:55 a.m. March 25, 2014 - PR Newswire - PRF
ARIAD Announces Initiation of Pivotal Phase 2 ALTA Trial of AP26113 in Patients with Non-Small Cell Lung Cancer 7:35 a.m. March 24, 2014 - BusinessWire - BZX
Financial Results, Clinical Study Updates, Clinical Trial Results, Business Spin-Offs, and New Joint Ventures - Analyst Notes on ARIAD, NewLink, Puma Biotechnology, Theravance, and Ohr Pharmaceutical 8:00 a.m. March 12, 2014 - PR Newswire - PRF
Most Active Equities Technical Snapshot: SandRidge Energy, Ariad Pharma, Groupon, and Vodafone 10:12 a.m. March 11, 2014 - PR Newswire - PRF
New Appointments, Contract Extensions, Share Price Movements, Conference Schedules, and Closing of Public Offerings - Analyst Notes on Ariad, Novavax, Fonar, bluebird, and Cara 7:24 a.m. March 5, 2014 - PR Newswire - PRF
Workday Upgraded to $150 a Share; Ariad Pharmaceuticals Q4 Loss Widens 12:34 a.m. Feb. 28, 2014 - ACCESSWIRE
ARIAD Reports 2013 Financial Results and Outlines Key Objectives for 2014 7:35 a.m. Feb. 25, 2014 - BusinessWire - BZX
ARIAD to Present at the Cowen and Company 34th Annual Health Care Conference 7:35 a.m. Feb. 24, 2014 - BusinessWire - BZX
ARIAD Expands Its Board of Directors with Appointment of Alexander J. Denner, Ph.D. of Sarissa Capital Management 7:35 a.m. Feb. 21, 2014 - BusinessWire - BZX
Facebook to Buy Messaging App WhatsApp; Garmin Ltd. Hits New 1-year High on Earnings 12:29 a.m. Feb. 20, 2014 - ACCESSWIRE
ARIAD to Present at the RBC Capital Markets Healthcare Conference 7:35 a.m. Feb. 19, 2014 - BusinessWire - BZX
ARIAD to Host Conference Call and Webcast Discussion of Fourth Quarter and Year-End 2013 Financial Results on February 25, 2014 7:35 a.m. Feb. 10, 2014 - BusinessWire - BZX
TrendingWallStreet.com Announces Coverage on DDD, ARIA, ENIP, and LATF 12:24 a.m. Feb. 6, 2014 - ACCESSWIRE

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Novo's CagriSema Trial Shows Promising Obesity Results

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

Servier's Data on Tovorafenib Shows Promise in pLGG

New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...

CARsgen's CAR-T Breakthrough on China's Insurance List

A Game Changer for CAR-T Therapies There's a breeze of optimism blowing from Shanghai these days—a rare sensation in this market of endless skirmishes. CARsgen Therapeutics Holdings Limited, a company entrenched in the development of cutting-edge CAR T-cell therapies, just notched a victory. They've announced that their CAR T-cell therapy product, satricabtagene...

Lilly's Obesity Breakthroughs: A Step Beyond the Scale

Pushing the Boundaries of Obesity Treatment Alright, let's cut through the noise and get to what really matters here. Eli Lilly is taking on obesity treatment like it's Clash of the Titans at this year's ObesityWeek 2026 in Washington, D.C. Forget just dropping pounds—Lilly wants to reshape how we think about obesity entirely. They're not just leaning into the scale,...

WeaveGrid Powers EVConnectNC: Charging Incentives Launched

Transforming Utilities with EVConnectNC In a fresh move by WeaveGrid, North Carolina's Electric Cooperatives have teamed up to roll out EVConnectNC. This innovative program aims to manage the burgeoning demand for electric vehicle (EV) charging in rural and suburban areas under North Carolina's cooperative umbrella. Think of it as a smart way to handle new loads without...

WHO and RCSI Bahrain Join Forces on Health Initiatives

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Breakthrough T1D Pushes Global T1D Awareness Forward

Shining a Light on T1D with Global Efforts In a world where a change in lifestyle can happen at the drop of a hat, Breakthrough T1D is making waves by expanding their global "See T1D" campaign in honor of World Diabetes Day. This isn't your run-of-the-mill awareness push—this is about propelling an understanding of what life truly entails for those living with type 1...

EZaccessMD Data Breach: Class Action Lawsuit Looms

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...

Retirement Dreams Dashed: 61% Withdraw Early

By Olivia Taylor Updated Nov 14, 2026 Category News Views 298

Retirement Caught in the Crosshairs Just when you think the path to retirement might clear up, life slaps down older workers with economic reality. A recent LiveCareer survey underscores this financial mess, revealing that 61% of those 50 and older are raiding their own retirement funds to make ends meet. It's enough to make one's head spin. Inflation: The Unwanted Guest...

Luvme Hair Offers Wig Variety for Winter Fashion

Adding Flair to Winter Looks A style kick-off from the fashion world: Luvme Hair is flipping the table on winter wardrobes with a new collection of wigs. As the weather ramps up the need for thick coats and cumbersome layers, these long hairstyles offer a little extra swing, bringing dimension into the mix. Fancy a change from traditional winter hibernation? Here’s what...